Is there a role for probiotics in irritable bowel syndrome?

Digestive and Liver Disease

Volumn 38, Issue SUPPL. 2, 2006, Pages

  Camilleri, Michael ^a  

^a Mayo Clinic   (United States)

Author keywords

Bifidobacteria; Irritable bowel syndrome; Lactobacilli; Probiotics; VSL 3

Indexed keywords

PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL 3;

ARTICLE; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; STREPTOCOCCUS SALIVARIUS;

HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 33846452536     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(07)60007-3     Document Type: Article

References (33)

1. Rolfe R. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 130 (2000) 396S-402S
2. de Roos N., and Katan M. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 71 (2000) 405-411
3. Guarner F., and Malagelada J. Gut flora in health and disease. Lancet 361 (2003) 512-519
4. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 42 (1998) 2-7
5. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 38 (2004) S104-S106
6. Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol 288 (2005) G417-G421
7. Mimura T., Rizzello F., Helwig U., Poggioli G., Schriber S., and Talbot I. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
8. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K., and Brigidi P. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo controlled trial. Gastroenterology 124 (2003) 1202-1209
9. Nobaek S., Johansson M., Molin G., Ahrne S., and Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95 (2000) 1231-1238
10. Kim H., Camilleri M., McKinzie S., Lempke M., Burton D., and Thomforde G. A randomized controlled trial of a probiotic, VSL #3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17 (2003) 895-904
11. O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., and Chen K. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128 (2005) 541-551
12. Kamath P., Phillips S., O'Connor M., Brown M., and Zinsmeister A. Colonic capacitance and transit in man: modulation by luminal contents and drugs. Gut 31 (1990) 443-449
13. Binder H., and Mehta P. Short-chain fatty acids stimulate active sodium and chloride absorption in vitro in the rat distal colon. Gastroenterology 96 (1989) 989-996
14. Brigidi P., Swennen E., Vitali B., Rossi M., and Matteuzzi D. PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. Int J Food Microbiol 81 (2003) 203-209
15. Kim H., Vazquez Roque M., Camilleri M., Stephens D., Burton D., Baxter K., et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17 (2005) 687-696
16. Ma D., Forsythe P., and Bienenstock J. Live Lactobacillus reuteri is Essential for the inhibitory effect on tumor necrosis alpha-induced interleukin-8 expression. Infection and Immunity 72 (2004) 5308-5314
17. Borruel N., Carol M., Casellas F., Antolin M., de Lara F., and Espin E. Increased mucosal tumor necrosis factor a production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51 (2002) 659-664
18. Pathmakanthan S., Li C., Cowie J., and Hawkey C. Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon. Journal of Gastroenterology and Hepatology 19 (2004) 166-173
19. Borruel N., Casellas F., Antolin M., Llopis M., Carol M., and Espiin E. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 98 (2003) 865-870
20. McCarthy J., O'Mahony L., O'Callaghan L., Sheil B., Vaughan E., and Fitzsimmons N. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52 (2003) 975-980
21. Menard S., Candalh C., Bambou J., Terpend K., Cerf-Bensussan N., and Heyman M. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53 (2004) 821-828
22. Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., and Yachimec C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121 (2001) 580-591
23. Malinen E., Rinttila T., Kajander K., Matto J., Kassinen A., Krogius L., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100 (2005) 373-382
24. Thaysen E., and Pedersen L. Idiopathic bile acid catharsis. Gut 17 (1976) 965-970
25. Brydon W., Nyhlin H., Eastwood M., and Merrick M. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhea. Eur J Gastroenterol Hepatol 8 (1996) 117-123
26. Chadwick V., Gaginella T., Carlson G., Debongnie J., Phillips S., and Holfmann A. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 94 (1979) 661-674
27. Bampton P., Dinning P., Kennedy M., Lubowski D., and Cook I. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol 282 (2002) G443-G449
28. Tanaka H., Hashiba H., Kok J., and Mierau I. Bile salt hydrolase of Bifidobacterium longum - biochemical and genetic characterization. Applied and Environmental Microbiology 66 (2000) 2502-2512
29. Tannock G., Dashkevicz M., and Feighner S. Lactobacilli and bile salt hydrolase in the murine intestinal tract. Applied and Environmental Microbiology 55 (1989) 1848-1851
30. Moser S., and Savage D. Bile salt hydrolase activity and resistance to toxicity of conjugated bile salts are unrelated properties in lactobacilli. Applied and Environmental Microbiology 67 (2001) 3476-3480
31. Kurdi P., Tanaka H., van Veen H., Asano K., Tomita F., and Yokota A. Cholic acid accumulation and its diminution by short-chain fatty acids in Bifidobacteria. Microbiology 149 (2003) 2031-2037
32. Tanaka H., Doesburg K., Iwasaki T., and Mierau I. Screening of lactic acid bacteria for bile salt hydrolase activity. J Dairy Sci 82 (1999) 2530-2535
33. Bazzocchi G., Gionchetti P., Almerigi P., Amadini C., and Campirei M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 34 (2002) S48-S53